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Susanne McCabe
I ﬁ  nd the arguments raised by the PLoS Medicine editors very 
useful [1] as I had not considered that a scientiﬁ  c community 
would tolerate barring access to registers of trials. It leaves 
huge gaps for exploitation by privileged groups.
It is not only colleagues in research and allied professions 
who need access but the global community, including 
members of the public wherever they live, those who 
participate in trials and those who will be on the receiving 
end of their outcomes.
The annual reports of research ethics committees (RECs) 
are supposedly in the public domain after approval by 
Strategic Health Authorities in the UK. But very few members 
of the public know of their existence or how to access 
them. Approaches to individual committees even now can 
meet with varied reactions, from suspicious, defensive, or 
hostile—reluctantly sending one report, quizzing as to which 
organisation the enquirer belongs to and why they should 
want one—to extremely welcoming of interest and discussion.
The annual reports should be easily accessible online by 
now, surely, but they are not. The activities of RECs and 
information on what research is being carried out in the 
name of society as a whole largely remain hidden from public 
view.
There is no information about public access on COREC 
(Central Ofﬁ  ce for Research Ethics Committees; www.corec.
org.uk) or OREC (Ofﬁ  ce for Research Ethics Committees; 
www.orecni.org.uk). COREC has not been open about 
dealing with issues of concern raised with them in the past. 
They do state that public interest is welcome now, so it 
would show a real commitment to making research activity 
more open if they would show support for totally open 
access to a register and to promote that through their Web 
site.  
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Unregistered Trials Are Unethical
Eswar Krishnan 
Current journal requirements forcing clinical trials to be 
registered [1] are insufﬁ  cient and are unlikely to solve the 
problem of negative trials never even making it to a journal. 
Most of the patients consenting to clinical trials do so out of 
altruism. It is a great betrayal of their trust to suppress clinical 
trial data. I suggest that institutional review boards refuse to 
allow human experimentation unless the protocol is ﬁ  led in a 
central (online) repository. The primary data should also be 
required to be in the public domain (say, within 1–2 years after 
completion). Data obtained by appealing to altrusitic instincts, 
similar to money in public charities, are not proprietary 
information, nor can physicians cash out the trust of their 
patients. In reality, it is the pharmaceutical industry that stands 
to gain the most if data are made public as such data inform 
future research and help smaller, innovative companies avoid 
redundancy. Voluntarily sticking to higher standards of ethics 
will raise societal respect for the industry (currently being 
battered for greed) and attract a more talented workforce, and 
may even help the current efforts to reform the tort law.  
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Free Community Science and the Free 
Development of Science
Richard Stallman
In free community science, where large numbers of 
scientists participate as volunteers in a single project, the 
ideal of scientiﬁ  c cooperation ﬁ  nds a new expression. 
Free community science was inspired by the free software 
movement, which itself was inspired by the application of the 
ideal of scientiﬁ  c cooperation, as it was applied to software 
development by the operating system developers of the 
Massachusetts Institute of Technology Artiﬁ  cial Intelligence 
Lab in the 1970s. This ideal has suffered for two decades from 
corporate pressure to privatize science, so it is very gratifying 
to see that the free software movement can today help 
reinvigorate the principle that inspired it. 
The ideal of scientiﬁ  c cooperation goes beyond the 
conduct of individual projects. Scientiﬁ  c cooperation is 
also being reinvigorated today through the open-access 
movement, which promotes the public’s freedom to 
redistribute scientiﬁ  c and scholarly articles. In the age 
of the computer networks, the best way to disseminate 
scientiﬁ  c writing is by making it freely accessible to all and 
letting everyone redistribute it. I give a vote of thanks to the 
Public Library of Science for leading the campaign that is 
now gaining momentum. When research funding agencies 
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pressure journals to allow free redistribution of new articles 
they fund, they should apply this demand to the old articles 
“owned” by the same publishers—not just to papers published 
starting today. 
Journal editors can promote scientiﬁ  c cooperation by 
adopting standards requiring internet publication of the 
supporting data and software for the articles they publish. 
The software and the data will be useful for other research. 
Moreover, research carried out using software cannot be 
checked or evaluated properly by other scientists unless they 
can read the source code that was used. 
A signiﬁ  cant impediment to publication and cooperation 
comes from university patent policies. Many universities 
hope to strike it rich with patents, but this is as foolish as 
playing the lottery, since most “technology licensing ofﬁ  ces” 
don’t even cover their operating costs. Like the Red Queen, 
these universities are running hard to stay in the same place. 
Society should recognize that funding university research 
through patents is folly, and should fund it directly, as in 
the past. Meanwhile, laws that encourage universities to seek 
patents at the expense of cooperation in research should be 
changed. 
Another impediment comes from strings attached to 
corporate research funding. Universities or their public 
funding agencies should ensure private sponsors cannot 
block research they do not like. These sponsors must never 
have the power to veto or delay publication of results—or to 
intimidate the researchers. Thus, sponsors whose interests 
could be hurt by publication of certain possible results 
must never be in a position to cut the funding for a speciﬁ  c 
research group. 
The free software movement, the free redistribution policy 
of this journal, and the practice of free community science for 
developing diagnostic disease classiﬁ  cations [1] are all based 
on the same fundamental principle: knowledge contributes to 
society when it can be shared and developed by communities. 
All three face opposition from those who would like to 
privatize knowledge and charge tolls for its use. In the free 
software movement we have 20 years’ experience in resisting 
this opposition, and we have built up considerable strength 
and momentum. We can give the other two movements a 
boost, so they can advance more quickly.  
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